Mosquito bites as a research tool: can scientists reproduce malaria infection on demand?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy, adult volunteers aged 18 to 45 years old * Tympanic body temperature \< 37.5°C * Residence in Lambaréné or surroundings for the period of the trial * History of long-term residence (at least 5 years) in Gabon * Willingness to take two curative anti-malarial regimens * Reachable (24/7) by mobile phone during the CHMI and follow-up * A body mass index \<35 Exclusion Criteria: * Haemoglobin level \< 11 g/dl for female volunteers and \< 11.5 g/dl for male volunteers * Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period * Prior receipt of an investigational malaria vaccine * Immunization with more than 3 other vaccines within the past month. * Positive for hepatitis B surface antigen (HBs-antigen) * Seropositive for hepatitis C virus (antibodies to HCV). * Positive HIV test * Abnormal level of transaminase (ALAT, ASAT) * Have been treated for malaria disease with an antimalarial drug or an antibiotic active on malaria parasites over the previous 28 days of the inoculation. * Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe and chronic (more than 14 days) infections, immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). * Use of immunoglobulins or blood products within 3 months prior to enrolment. * Sickle cell disease or any clinically relevant blood disorder. * History of a serious psychiatric condition that may affect participation in the study. * Positive urine pregnancy test or breastfeeding * Any other serious chronic illness requiring hospital specialist supervision * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g per day. * Suspected or known injecting drug abuse in the 5 years preceding enrolment. * Contraindications to the use of the first-line anti-malarial medications: artemether/lumefantrine or atovaquone/proguanil. * Subjects unable to be closely followed for social, geographic or psychological reasons. * Any clinically significant abnormal finding on biochemistry or haematology blood tests, urine analysis or clinical examination. * History of seizure. * Any other significant disease, disorder or finding which, in the opinion of the Investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.